SAN

80.79

+2.1%↑

UCB

272.5

-0.58%↓

SHL.DE

38.22

+1.25%↑

ARGX

705.8

+3.89%↑

VIE

35.35

+2.46%↑

SAN

80.79

+2.1%↑

UCB

272.5

-0.58%↓

SHL.DE

38.22

+1.25%↑

ARGX

705.8

+3.89%↑

VIE

35.35

+2.46%↑

SAN

80.79

+2.1%↑

UCB

272.5

-0.58%↓

SHL.DE

38.22

+1.25%↑

ARGX

705.8

+3.89%↑

VIE

35.35

+2.46%↑

SAN

80.79

+2.1%↑

UCB

272.5

-0.58%↓

SHL.DE

38.22

+1.25%↑

ARGX

705.8

+3.89%↑

VIE

35.35

+2.46%↑

SAN

80.79

+2.1%↑

UCB

272.5

-0.58%↓

SHL.DE

38.22

+1.25%↑

ARGX

705.8

+3.89%↑

VIE

35.35

+2.46%↑

Kodu・Aktsiate loetelu・Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi SA

Suletud

SektorTervishoid

84.95 1.37

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

83.8

Max

85.05

Põhinäitajad
By Trading Economics
Sissetulek	-33M 43M
Müük	7.9M 218M
P/E Sektori keskmine	35.869 63.808
Aktsiakasum	0.834
Kasumimarginaal	19.539
Töötajad	1,950
EBITDA	-21M 63M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+3.46% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	6. mai 2026

Turustatistika
By TradingEconomics
Turukapital	353M 4.3B
Eelmine avamishind	83.58
Eelmine sulgemishind	84.95

Uudiste sentiment

By Acuity

50%

156 / 348 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

51.1 / N/A Toetus ja vastupanu

Laboratorios Farmaceuticos Rovi SA Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

14. apr 2026, 23:36 UTC

Omandamised, ülevõtmised, äriostud

China-Backed Yancoal Australia to Buy Kestrel Coal Mine Stake For Up to $2.4 Billion -- Update

14. apr 2026, 23:24 UTC

Kuumad aktsiad

Stocks to Watch: Gloo, Broadcom, GitLab

14. apr 2026, 22:42 UTC

Omandamised, ülevõtmised, äriostud

China-Backed Yancoal Australia to Buy Kestrel Coal Mine Stake For Up to $2.4 Billion

14. apr 2026, 21:32 UTC

Suurimad hinnamuutused turgudel

GitLab Shares Rise on Expanded Google Cloud Collaboration

14. apr 2026, 23:54 UTC

Market Talk

Nikkei May Rise as Fears About Energy Shortage Ease -- Market Talk

14. apr 2026, 23:34 UTC

Market Talk

Gold Edges Lower on Possible Technical Correction -- Market Talk

14. apr 2026, 22:54 UTC

Tulu

BRP: Amendment Mainly Leads to 25% Tariff on Total Value of Imported Snowmobiles and Majority of ORV Models, Replacing Previous 50% Tariff on Applicable Metal Content Only >DOO.T

14. apr 2026, 22:54 UTC

Tulu

BRP: Suspending Guidance Following Amendment of Section 232 Tariffs on Steel, Aluminum and Copper Imports Into U.S., Which Came Into Effect on April 6 >DOO.T

14. apr 2026, 22:54 UTC

Tulu

BRP: Currently Estimates Potential Incremental Tariff Cost Related to This Amendment in Excess of $500M for Remainder of Yr >DOO.T

14. apr 2026, 22:54 UTC

Tulu

BRP: Suspends FY27 Guidance Due to Changes to U.S. Tariff Environment

14. apr 2026, 22:17 UTC

Omandamised, ülevõtmised, äriostud

Yancoal Australia: Targets Deal Completion Toward End of 3Q

14. apr 2026, 22:17 UTC

Omandamised, ülevõtmised, äriostud

Yancoal Australia: Acquisition Diversifies Portfolio; Met Coal Share to Rise to 22%

14. apr 2026, 22:17 UTC

Omandamised, ülevõtmised, äriostud

Yancoal Australia: Asset 'Strong Strategic Fit'; to Positively Add Production, Cash Flow

14. apr 2026, 22:16 UTC

Omandamised, ülevõtmised, äriostud

Yancoal Australia: Intends to Fund Acquisition With Cash, 5-Year Loan Facility

14. apr 2026, 22:15 UTC

Omandamised, ülevõtmised, äriostud

Yancoal Australia: Contingent Consideration Linked to Average Annual Prices For 5 Years

14. apr 2026, 22:14 UTC

Omandamised, ülevõtmised, äriostud

Yancoal Australia: Deal Includes Contingent Cash Consideration Up to $550 Million

14. apr 2026, 22:13 UTC

Omandamised, ülevõtmised, äriostud

Yancoal Australia: Deal Includes $1.85 Billion Upfront Consideration

14. apr 2026, 22:12 UTC

Omandamised, ülevõtmised, äriostud

Yancoal Australia: To Buy Kestrel Stake From EMR Capital, Adaro Capital

14. apr 2026, 22:12 UTC

Omandamised, ülevõtmised, äriostud

Yancoal Australia: To Buy Kestrel Stake For Up to $2.4 Billion

14. apr 2026, 22:10 UTC

Omandamised, ülevõtmised, äriostud

Yancoal Australia: to Acquire 80% Interest in Kestrel Coal Mine

14. apr 2026, 20:50 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Basic Materials Roundup: Market Talk

14. apr 2026, 20:33 UTC

Omandamised, ülevõtmised, äriostud

Microsoft Is Buying 3,200 Acres For a Data Center. This Utility Stock Is Rising. -- Barrons.com

14. apr 2026, 20:32 UTC

Kuumad aktsiad

Stocks to Watch: JPMorgan, American Airlines, LVMH, BlackRock -- WSJ

14. apr 2026, 19:59 UTC

Omandamised, ülevõtmised, äriostud

Microsoft Is Buying 3,200 Acres For a Data Center. This Utility Stock Is Rising. -- Barrons.com

14. apr 2026, 19:38 UTC

Tulu

Johnson & Johnson Financial Chief Sees 'Clear Line of Sight' to Double-Digit Growth by 2030 -- Barrons.com

14. apr 2026, 19:27 UTC

Market Talk

U.S. Natural Gas Futures Extend Losing Streak -- Market Talk

14. apr 2026, 19:21 UTC

Market Talk

Uudisväärsed sündmused

Oil Futures Retreat on Hopes for U.S.-Iran Peace Talks -- Market Talk

14. apr 2026, 19:09 UTC

Omandamised, ülevõtmised, äriostud

Apple and Amazon Partner on Satellite Deal. Why It Makes Sense. -- Barrons.com

14. apr 2026, 18:30 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

14. apr 2026, 18:30 UTC

Market Talk

Treasury Yields, Dollar Fall as Markets Price Higher Odds of Fed Cuts -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Laboratorios Farmaceuticos Rovi SA Prognoos

Hinnasiht

By TipRanks

3.46% tõus

12 kuu keskmine prognoos

Keskmine 86.75 EUR 3.46%

Kõrge 90 EUR

Madal 83.5 EUR

Põhineb 2 Wall Streeti analüütiku instrumendi Laboratorios Farmaceuticos Rovi SA 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

2 ratings

Osta

Hoia

Müü

Põhineb 2 analüütiku instrumendi Laboratorios Farmaceuticos Rovi SA aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

51.1 / N/AToetus ja vastupanu

Recent bullish events outweigh bearish events.

Bearish events outweigh bullish events.

Sentiment

By Acuity

156 / 348 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; and hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, Fibrilin, and Sodium Heparin Rovi. It also provides contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, and sachets. Laboratorios Farmaceuticos Rovi, S.A. was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.